CEO Update: August 2021

CEO Update: August 2021

InSitu Biologics has had a very productive summer. We received positive pre-clinical animal study results on our lead product, had positive regulatory interactions with the FDA, further developed our manufacturing capabilities, and made progress towards future funding...
CEO Update: April 2021

CEO Update: April 2021

InSitu Biologics is off to a fast start in 2021.  We completed a successful financing round, made great strides in our R&D efforts, and held our first Medical Advisory Board meeting. For additional information regarding our progress, please take some time to read...
CEO Update: December 2020

CEO Update: December 2020

Insitu Biologics had several key accomplishments in 2020, setting the stage for an even better 2021. We significantly reduced our shareholders-of-record, renegotiated and renewed our license agreement with LifeCore Biomedical, and conducted successful bench and animal...
CEO Update: August 2020

CEO Update: August 2020

InSitu Biologics has made considerable progress executing our business plan over the past several months, even in the midst of ongoing COVID-19 challenges.  We recently raised over $2 million in a convertible note financing round, received a pre-investigational new...
CEO Update: April 2020

CEO Update: April 2020

InSitu Biologics has continued to make great strides over the past few months. We have successfully submitted our Pre-IND application to the FDA, as well as applied for a National Institute of Health federal grant to support our development costs. During this time of...